IL2 and cancer: In addition, deletion of Smad3 also enhanced the anticancer activities of NK cells by increasing the levels of granzyme B, interleukin (IL)-2 and IFN-γ locally within the cancer microenvironment and in the systemic circulation (Fig. 2d,e).